DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a ...
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development Cash position of $76.3 million as of December 31, 2025 expected to fund current ...
Instil Bio is calling it quits on its lead tumor-infiltrating lymphocyte therapy and four corresponding programs, a major overhaul of the company’s priorities that’s resulting in 60% of its staff ...
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1 ...
Instil Bio, Inc. (TIL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...
Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ...
Instil Bio, Inc. announced the clearance of an Investigational New Drug (IND) application for its drug AXN-2510 by the FDA, enabling the company to begin a phase 1 trial before the end of 2025. This ...
The average one-year price target for Instil Bio (NasdaqCM:TIL) has been revised to $67.32 / share. This is an increase of 24.53% from the prior estimate of $54.06 dated March 25, 2026. The price ...
Instil was able to sell more shares and at a higher price than it initially planned. The Dallas-based company set preliminary IPO terms on Monday for an offering of 13.9 million shares in the range of ...
The Instil Bio Life Sciences Campus will be at 18404-18412 Oxnard Street in the neighborhood of Tarzana in the San Fernando Valley. CBRE said that, with clinical manufacturing operational, the recent ...
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
In January 2026, Axion Bio, Inc., a wholly owned subsidiary of Instil, discontinued clinical development of AXN-2510 and entered into a termination agreement with ImmuneOnco Biopharmaceuticals ...
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
DALLAS, March 27, 2026 (GLOBE NEWSWIRE)-- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results